Federal Circuit arguments in Myriad may worry biotech industry
The Federal Circuit's Myriad review could provide clarity about the scope of recent Supreme Court patent-eligibility decisions, but one pharma IP practitioner worries that “the biotech industry might feel storm-tossed after these oral arguments”
The Federal Circuit last week heard oral arguments in the case involving Myriad Genetics’ BRCA1/BRCA2 diagnostic tests. In its opening brief, Myriad said the case will decide whether it can enforce its patents or whether it “can patent almost nothing...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.